Investor · 1 deal
Every published round BBF1 IIF took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Fibrotech | Series A | 10 Feb 2009 | $3m | Participant | bionity.com, Brandon Capital portfolio |
Companies BBF1 IIF has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Fibrotech | 10 Feb 2009, Series A | 1 | 0 |
Fund closes reported for BBF1 IIF, as distinct from the investments it has made.
Companies BBF1 IIF has backed that another company then bought. An exit for the holding, not a deal BBF1 IIF did.
Stories naming BBF1 IIF. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Fibrotech Therapeutics raised $3 million in Series A backing from Brandon Capital-managed funds MRCF, BBF1 IIF and Uniseed to advance fibrosis drug FT011 through Phase Ib trials.